Navigation Links
HIV Experts Propose New Approach to Eradicate HIV in Latest Issue of Science

Tibotec joins other leaders from academia, industry and government in collaboration to fight HIV

YARDLEY, Pa., March 5 /PRNewswire/ -- A group of leading HIV experts call for the exploration of a new approach to treating HIV - one that could ultimately help eradicate the virus - through a collaboration involving academia, industry, government and patient advocates. This new approach to HIV treatment is discussed in a perspective article published in the March 6, 2009 issue of Science.

The article, provocatively titled, "The Challenge of a Cure for HIV Infection," is authored by three academics, Doug Richman, UCSD; David Margolis, UNC; Warner Greene, UCSF; one community advocate, the late Martin Delaney, Project Inform; and two industry scientist leaders, Daria Hazuda, Merck; Roger Pomerantz, Tibotec.

This diverse group came together to set a goal for the next era in HIV therapeutics - drug free remission - and assemble a coordinated initiative to identify potential interventions and a clinical assessment to reach this goal. The initiative, which the authors coined a "collaboratory," aims to accelerate the progress of individual research groups, harness the drug discovery capabilities of industry and utilize the government to coordinate regulatory approaches and mobilize funding.

"A successful vaccine or microbicide still remains a significant challenge in spite of billions of dollars and years of research, and having millions of people on lifelong highly active antiretroviral therapy (HAART) may not be sustainable," said Roger Pomerantz, M.D., FACP, President of Tibotec R&D. "At Tibotec, we have a heritage of partnership and collaboration, and we are committed to forging new approaches with others to develop HIV therapeutics that could finally eradicate the disease."

Envisioning the Post-HAART Era

Since the arrival of HAART more than a decade ago, people diagnosed with HIV have gained a lengthened life expectancy and improved quality of life. Today, patients newly infected with HIV can expect to live 40-50 years as a result of HAART. However, HAART is not the optimal solution for HIV - it requires lifelong therapy, the medication can cause various side effects and the effects of long-term HAART are not yet known. And, if HAART is interrupted, the virus rapidly replicates and the patient's immune system is attacked once more. HAART suppresses the virus, but it is unable to eradicate it completely. As a result, the virus persists in latently infected cells (HIV latency) and other reservoirs. The authors conclude that eradicating the virus from these cells and reservoirs is a crucial approach in the pursuit for therapies that could provide drug free remission, and potentially a cure.

The three academics and two industry scientists who authored the Science article have individually been involved in independent studies of HIV latency and reservoirs, and there has been significant progress in understanding these conditions. However, the authors point out, such discrete studies may be duplicative and slow to build up a complete picture.

"A flexible, collaborative private-public joint venture has the possibility to catalyze progress in the search for therapeutic interventions that can eradicate HIV and result in drug-free remission for HIV patients," said Paul Stoffels, M.D., Company Group Chairman, Johnson & Johnson. "This new approach of 'open innovation' is critical if we are to meet the really big challenges that remain today in the HIV field, such as eradication."

About Tibotec

Tibotec, Inc., based in Yardley PA, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with head office in Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.

Media Contact: Karen Manson +32 479 89 47 99 (mobile)

SOURCE Tibotec
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Experts examine causes, treatment and prevention of glaucoma
2. Names Consumer Affairs Advocate, Healthcare Experts to Provide Free Educational Support for Seniors
3. Policy experts urge scrutiny of senior tax breaks
4. Interview with GI Experts: Discussions in Clostridium difficile
5. Burn rehabilitation experts at UT Southwestern outline best treatments for post-burn itching
6. Rush University Medical Center experts present latest research findings at AAOS meeting
7. Health experts urge supermarket pharmacies to get smart about free antibiotics
8. Experts Call for FDA Regulation of Tobacco Products
9. Experts in Government, Public Health, Public Policy and Science Outline Blueprint for Reducing Death and Disease From Tobacco in the United States
10. Avon Foundation Convened Breast Cancer Experts in Miami to Address Prevention Strategies at Annual Forum
11. International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... located in central Michigan, have come together on Thanksgiving Day to share the ... available for viewing on the Serenity Point YouTube channel, patients displayed what they ...
(Date:11/26/2015)... and Cambridge, ON (PRWEB) , ... November 26, ... ... the availability of a real-time eReferral system for diagnostic imaging in the Waterloo ... X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical record ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... Viejo, CA (PRWEB) , ... November 26, 2015 ... ... users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This ... style options. These classically-influenced trailer titles work with any font, giving users limitless ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Calif. , Nov. 25, 2015  Amgen (NASDAQ: ... Biologics License Application (BLA) with the United ... for ABP 501, a biosimilar candidate to Humira ® ... adalimumab biosimilar application submitted to the FDA and represents ... Sean E. Harper , M.D., executive vice ...
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
(Date:11/25/2015)... , Nov. 25, 2015  Henry Schein, Inc., the ... to office-based dental, medical and animal health practitioners, will ... the Henry Schein ConnectDental® Pavilion , which brings ... of open solutions designed to help any practice or ... here for a schedule of experts appearing at ...
Breaking Medicine Technology: